[DOI] [PMC free article] [PubMed] [Google Scholar] Freyse E.-.J., Knospe S., Becher T., El Hag O., Gke B., Fischer U
The FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in late 2024, which ended the shortage-list justification that most large-scale compounding relied on
CDC data sounds alarm over obesity Data for 2023 from the Centers for Disease Control and Prevention, released this September, found that in 23 states, more than 1 in 3 adults had obesity
Across all six studies, the safety findings were consistent: no serious adverse events, no immunogenic responses, no changes in IGF-1, no glucose or insulin disruption
In our experience, the majority of our patients prefer injecting in the abdomen due to greater levels of subcutaneous fat being located within 2 inches of the umbilicus, otherwise known as the belly button
When you stick to the advice and live in a balanced way, you will see good results from weight loss in time